Henning T Mouridsen
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
08.10.2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
08.10.2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Mouridsen H, Thürlimann B, Robidoux A, Llombart-Cussac A, Gligorov J, Doughty J, Blackwell K, Beckmann M, Lønning P, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther 2010; 10:1825-1836.
30.09.2010Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
30.09.2010Expert Rev Anticancer Ther 2010; 10:1825-1836
Mouridsen Henning T, Thürlimann Beat, Robidoux Andre, Llombart-Cussac Antonio, Gligorov Joseph, Doughty Julie, Blackwell Kimberly, Beckmann Matthias W, Lønning Per, Gnant Michael